These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38996203)

  • 1. MOG CNS Autoimmunity and MOGAD.
    Moseley CE; Virupakshaiah A; Forsthuber TG; Steinman L; Waubant E; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200275. PubMed ID: 38996203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
    Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
    Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.
    Ambrosius W; Michalak S; Kozubski W; Kalinowska A
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
    Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
    Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.
    Jarius S; Ringelstein M; Schanda K; Ruprecht K; Korporal-Kuhnke M; Viehöver A; Hümmert MW; Schindler P; Endmayr V; Gastaldi M; Trebst C; Franciotta D; Aktas O; Höftberger R; Haas J; Komorowski L; Paul F; Reindl M; Wildemann B
    J Neurol; 2024 Jul; 271(7):4660-4671. PubMed ID: 38609667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.
    Höftberger R; Guo Y; Flanagan EP; Lopez-Chiriboga AS; Endmayr V; Hochmeister S; Joldic D; Pittock SJ; Tillema JM; Gorman M; Lassmann H; Lucchinetti CF
    Acta Neuropathol; 2020 May; 139(5):875-892. PubMed ID: 32048003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
    Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
    Front Immunol; 2020; 11():1188. PubMed ID: 32625206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
    Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
    Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
    Fujihara K; Cook LJ
    Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
    Goldman-Yassen A; Lee A; Gombolay G
    Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    Pache F; Ringelstein M; Aktas O; Kleiter I; Jarius S; Siebert N; Bellmann-Strobl J; Paul F; Ruprecht K
    J Neuroimmunol; 2021 Nov; 360():577699. PubMed ID: 34464830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
    Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.